

14

**REMARKS**

Claims 31-70 are pending in this case. In the instant Office Action, claims 44-47, 49, 50 and 52-54 were allowed, and claims 31-43, 48, 51, and 55-70 were rejected (final).

5        Claims 32-36, 38-40, 55, 56, 58, 59, 62 and 63 were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite. The use of the phrases "therapeutically effective", "a patient in need of", "inhibiting one or more cyclin dependent kinases" and "associated with a kinase" was objected to. The objection is addressed in this amendment. Withdrawal of the §112, second  
10        paragraph rejection is, therefore, respectfully requested.

      Claims 32-42 and 55-70 were rejected under § 112, first paragraph, on enablement grounds. The present amendment shows the listed diseases as being cured by inhibiting CDK1 and CDK2. There is substantial enablement for the inhibition of CDK2 in the application. As the enclosed Affidavit under  
15        37 C.F.R. 1.132 by inventor Dr. Timothy Guzi demonstrates, several of the inventive compounds additionally inhibited CDK1 (see EXHIBIT 1). Applicants strongly believe that the presently added activity data as well as the activity data already present in the application provide sufficient enablement for the inhibition of CDK1 and CDK2, thereby providing a method of treating diseases  
20        listed in the claims. Withdrawal of the §112, first paragraph rejection is, therefore, respectfully requested.

      Claims 31-43, 48, 51 and 55-70 were rejected under obviousness, provisional double patenting, over claims 1-19 and 21-47 of copending, co-owned, patent application, Serial No. 10/654,546. Applicants have amended  
25        both cases by moving the objected-to compounds from the '546 application to the present application. It is believed that the conflicting scope is now removed. Withdrawal of the double patenting rejection is, therefore, respectfully requested.

      There being no other rejections pending, Applicants believe that claims  
30        31-70 are in allowable condition and such an action is earnestly solicited.


      If the Examiner has any questions, the Examiner is invited to contact the undersigned.

**BEST AVAILABLE COPY**

15

December 16, 2005  
Schering-Plough Corporation  
2000 Galloping Hill Road  
Patent Department, K-6-1, 1990  
Kenilworth, NJ 07033  
Tel: (908) 298-5068  
Fax: (908) 298-5388

Respectfully submitted,



Dr. Palaiyur S. Kalyanaraman  
Attorney for Applicants  
Reg. No. 34,634

BEST AVAILABLE COPY